Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer

Oncology

Volumn 67, Issue 1, 2004, Pages 48-53

  Barone, C ^a   Cassano, A ^a   Pozzo, C ^a   D'Ugo, D ^a   Schinzari, G ^a   Persiani, R ^a   Basso, M ^a   Brunetti, I M ^b   Longo, R ^a   Picciocchi, A ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Gastric cancer; Laparoscopy; Long term follow up; Neoadjuvant therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MANNITOL;

ABDOMINAL DISEASE; ADULT; AGED; ALOPECIA; ANASTOMOSIS; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; ENDOSCOPIC ECHOGRAPHY; FATIGUE; FEMALE; FEVER; FOLLOW UP; GASTRECTOMY; GASTROINTESTINAL TOXICITY; HEMATOMA; HISTOPATHOLOGY; HUMAN; INFECTION; INFORMED CONSENT; LAPAROSCOPY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PHASE 2 CLINICAL TRIAL; PILOT STUDY; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; STOMACH HEMORRHAGE; THROMBOCYTOPENIA; WOUND INFECTION;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; EPIRUBICIN; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; GLUCURONATES; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PILOT PROJECTS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 5644225567     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080285     Document Type: Article

References (36)

1. Parkin DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J Clin 1999; 49: 33-64.
2. Neugut AI, Hayek M, Howe G: Epidemiology of gastric cancer. Semin Oncol 1996; 23: 281-291.
3. Wingo PA, Tong T, Bolden S: Cancer statistics, 1995. CA Cancer J Clin 1995; 45: 8-30.
4. Fuchs CS, Mayer RJ: Gastric carcinoma. N Engl Med 1995; 333: 32-41.
5. Siewert JR, Böttcher K, Stein HJ, Roder JD: Relevant prognostic factors in gastric cancer: Ten-year results of the German Gastric Cancer Study. Ann Surg 1998; 228: 449-461.
6. Kim JP: Surgical results in gastric cancer. Semin Surg Oncol 1999; 17: 132-138.
7. Kelsen DP: Adjuvant and neoadjuvant therapy for gastric cancer. Semin Oncol 1996; 23: 379-389.
8. Kim JP, Lee JH, Kim SJ, Yu HJ, Yang HK: Clinicopathologic characteristics and prognostic factors in 10,783 patients with gastric cancer. Gastric Cancer 1998; 1: 125-133.
9. Hundahl SA, Philips JL, Menck HR: The National Cancer Data Base report on poor survival of US gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on cancer staging, proximal disease, and the 'different disease' hypothesis. Cancer 2000; 88: 921-932.
10. Yao JC, Ajani JA: Therapy of localized gastric cancer: Preoperative and postoperative approaches. Ann Oncol 2002; 13(suppl 4):7-12.
11. Hermans J, Bonekamp JJ, Boon ME, ButaMm G, Ohyama S, Sasako M, Van de Velde CJH: Adjuvant therapy after curative resection for gastric cancer: Meta-analysis of randomized trials. J Clin Oncol 1993; 11: 1441-1447.
12. Hermans J, Bonekamp JJ: In reply. J Clin Oncol 1994; 12: 879-880.
13. Earle CC, Maroun JA: Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: Revisiting a meta-analysis of randomised trials. Eur J Cancer 1999; 35: 1050-1064.
14. Mari E, Floriani I, Tinazzi A, Bua A, Belfiglio M, Valentini M, Cascinu S, Barni S, Labianca R, Torri V: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: A meta-analysis of published randomized trials. Ann Oncol 2000; 11: 837-843.
15. Panzini I, Gianni L, Fattori PP, Tassinari D, Imola M, Fabbri P, Arcangeli V, Drudi G, Canuti D, Fochessati F, Ravaioli A: Adjuvant chemotherapy in gastric cancer: A meta-analysis of randomized trials and comparison with previous meta-analyses. Tumori 2002; 1: 21-27.
16. Hu JK, Chen ZX, Zhou ZG, Zhang B, Tian J, Chen JP, Wang L, Wang CH, Chen HY, Li YP: Intravenous chemotherapy for resected gastric cancer: Meta-analysis of randomized controlled trials. World J Gastroenterol 2002; 8: 1023-1028.
17. MacDonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NL, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JH, Martenson JA: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730.
18. Wils J: Treatment of gastric cancer. Curr Opin Oncol 1998; 10: 357-361.
19. Fink U, Stein HJ, Schuhmacher C, Wilke HJ: Neoadjuvant chemotherapy for gastric cancer: Update. World J Surg 1995; 19: 509-516.
20. Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA: Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 1999; 229: 303-308.
21. Takiguchi N, Oda K, Suzuki H, Wakatsuki K, Nunomora M, Kouda K, Saito N, Nakajima N: Neoadjuvant chemotherapy with 5-fluorouracil (5-FU) or low dose cisplatinum (CDDP) + 5-FU in the treatment of gastric carcinoma with serosal invasion. J Clin Oncol 2000; 19: 300a (abstract 1178).
22. Songun I, Keizer HJ, Hermans J, Klementschitsch P, deVries JE, Wils JA, van der Bijl J, van Krieken JH, van de Velde CJ: Chemotherapy for operable gastric cancer: Results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG). Eur J Cancer 1999; 35: 558-562.
23. Niederhuber JE: Neoadjuvant therapy. Ann Surg 1999; 229: 309-312.
24. Yano M, Tsujinaka T, Shiozaki H, Inoue M, Sekimoto M, Doki Y, Takiguchi S, Imamura H, Taniguchi M, Monden M: Appraisal of treatment strategy by staging laparoscopy for locally advanced gastric cancer. World J Surg 2000; 24: 1130-1135.
25. Barone C, Corsi DC, Pozzo C, Cassano A, Fontana T, Noviello MR, Landriscina M, Colloca G, Astone A: Treatment of patients with advanced gastric carcinoma with a 5-fluorouracil-based or a cisplatin-based regimen: Two parallel randomized phase II studies. Cancer 1998;82: 1460-1467.
26. Sobin LH, Wittekind C (eds): International Union against Cancer: TNM Classification of Malignant Tumours, ed 5. New York, Wiley-Liss, 1997.
27. Miller AB, Hoogstarten B, Staquet M, Winckler A: Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
28. Thall PF, Simon RM, Esthey EH: New statistical strategy for monitoring safety and ef. cacy in single-arm clinical trials. J Clin Oncol 1996; 14: 296-303.
29. Siewert JR, Böttcher K, Roder JD, Busch R, Hermanek P, Meyer HJ: Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group. Br J Surg 1993; 80: 1015-1018.
30. Bajetta E, Buzzoni R, Mariani L, Beretta E, Bozzetti F, Bordogna G, Aitini E, Fava S, Schieppati G, Pinotti G, Visini M, Ianniello G, Di Bartolomeo M: Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol 2002; 13: 299-307.
31. Neri B, Cini G, Andreoli F, Boffi B, Francesconi D, Mazzanti R, Medi F, Mercatelli A, Romano S, Siliani L, Tarquini R, Moretti R: Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up. Br J Cancer 2001; 84:878-880.
32. Schuhmacher CP, Fink U, Becker K, Busch R, Dittler H-J, Mueller J, Siewert JR: Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxirubicin, and cisplatinum. Closing results after 5 years of follow-up. Cancer 2001; 91: 918-927.
33. Rougier P, Mahjoubi M, Lasser P, Ducreux M, Oliveira J, Ychou M, Pignon JP, Elias D, Bellefqih S, Bognel C, Lusinchi A, Cvitkovic E, Droz J-P: Neoadjuvant chemotherapy in locally advanced gastric carcinoma - a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum. Eur J Cancer 1994; 30A:1269-1275.
34. Melcher AA, Mort D, Maughan TS: Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer. Br J Cancer 1996; 74: 1651-1654.
35. Fink U, Ott K, Dittler HJ, Helmberger H, Becker K, Busch R, Siewert JR: Neoadjuvant cisplatinum, leucovorin and fluorouracil (PLF) in adequately staged patients with locally advanced gastric carcinoma. J Clin Oncol 1999; 18: 272a (abstract 1044).
36. Becker K, Fumagalli U, Mueller JD, Fink U, Siewert JR, Höfler R: Neoadjuvant chemotherapy for patients with locally advanced gastric carcinoma: Effect on tumor cell microinvolvement of regional lymph nodes. Cancer 1999; 85: 1484-1489.